Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • University of Michigan • NCI-CCC Lymphoma Tumor Board Question
How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?
Answer from: Medical Oncologist at Academic Institution
Very hard situation. Probably this patient has received BTKi and venetoclax based therapies already. These cases are difficult to treat. There are no standard therapies.
Ideally, I try to take them to CAR-T therapy. The challenge is how to collect due to significant cytopenias due to extensiv...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Agree that this is very difficult. Combination of venetoclax + Btk inhibitor is safe and can be active in this situation. I also like the idea of anti-CD20 monoclonal antibody.
I am not aware of any data on the use of polatuzumab vedotin in Richter's, but this would be an option (+rituximab) ...